Trimeris Inc. About
TRIMERIS Inc. Trimeris (Nasdaq: TRMS) is a biopharmaceutical
company engaged in the discovery and development of new drugs for the treatment
of viral
diseases.
Their core technology platform focuses on compounds that inhibit viral replication
by blocking viral fusion with healthy immune cells. FUZEON®,
approved by the US FDA and European Commission in 2003, is the first in a new
class of anti-HIV drugs called fusion inhibitors. PRODUCT
INFORMATION More About Trimeris